title: [Efficacy, tolerability and safety of cyclosporine for microemulsion in the treatment of active rheumatoid arthritis. Open study].
abstract: Cyclosporine for microemulsion has been widely used in the treatment of rheumatoid arthritis (RA) with remarkably good results over progression of joint damage, as reported by the GRISAR Study. A local group in Argentina, performed a prospective, open label study (Neo-Ra-02), consisting of 12 centres which recruited 50 RA patients, who were followed during 6 months in order to assess efficacy, tolerability and safety of cyclosporine microemulsion in the treatment of RA. Efficacy parameters were: morning stiffness, functional evaluation (HAQ, Lee and Ritchie index) and laboratory and radiological (Larsen score) assessments. Safety parameters were: blood pressure and renal, liver and hematological laboratory data. Patients criteria for participation were: presence of active RA (as defined by the ACR), Steinbrocker anatomic and functional grade I to III, disease evolution no longer than 5 years, no previous history of hypertension, renal or liver disease and absence of DMARDs use during the previous 2 months. There was a statistically significant decrease in morning stiffness and in pain evolution. Improvement became evident after 4 weeks of treatment. Reduction of Ritchie index was significant also at 4 weeks and the same observation was made with tenderness and swollen joint scores. Regarding evolution of CRP and RF, a statistically significant reduction was observed only in positive RF. Safety parameters showed no significant increase in serum creatinine or uric acid: 6/50 patients developed mild hypertension with only a significant increase in systolic blood pressure in comparison with baseline. Cyclosporine microemulsion demonstrated efficacy with minimal adverse events (12% mild hypertension) when appropriately monitored and administered in low doses (3 mg/kg/day).
authors.affiliation: Hospital San Martín, La Plata, Argentina.
authors.forename: J C
authors.initials: JC
authors.lastname: Marcos
authors.forename: A
authors.initials: A
authors.lastname: Maccagno
authors.forename: E
authors.initials: E
authors.lastname: Gutfraind
authors.forename: A
authors.initials: A
authors.lastname: Garsd
authors.forename: D O
authors.initials: DO
authors.lastname: Messina
authors.forename: J
authors.initials: J
authors.lastname: Maldonado Cocco
authors.forename: C
authors.initials: C
authors.lastname: Battagliotti
authors.forename: C M
authors.initials: CM
authors.lastname: Onetti
authors.forename: G
authors.initials: G
authors.lastname: Tate
authors.forename: H O
authors.initials: HO
authors.lastname: Venarotti
authors.forename: H
authors.initials: H
authors.lastname: Grosman
authors.forename: E A
authors.initials: EA
authors.lastname: Díaz
authors.forename: A B
authors.initials: AB
authors.lastname: Otero
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D003404:Creatinine / Q000032:analysis; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004655:Emulsions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014527:Uric Acid / Q000032:analysis
chemical_list: D018501:Antirheumatic Agents; D004655:Emulsions; D014527:Uric Acid; D016572:Cyclosporine; D003404:Creatinine